125 related articles for article (PubMed ID: 2713222)
41. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
[TBL] [Abstract][Full Text] [Related]
42. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
43. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
44. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
Chang WH; Lin SK; Jann MW
J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
[TBL] [Abstract][Full Text] [Related]
45. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Cesková E; Svestka J
Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
[TBL] [Abstract][Full Text] [Related]
46. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
47. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):63-6. PubMed ID: 12107619
[TBL] [Abstract][Full Text] [Related]
48. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
49. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
50. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
Ko GN; Korpi ER; Kirch DG
J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
[TBL] [Abstract][Full Text] [Related]
51. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study.
Haas S; Beckmann H
Pharmacopsychiatria; 1982 Mar; 15(2):70-4. PubMed ID: 7043498
[TBL] [Abstract][Full Text] [Related]
52. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.
Sindrup SH; Brøsen K; Bjerring P; Arendt-Nielsen L; Larsen U; Angelo HR; Gram LF
Clin Pharmacol Ther; 1990 Dec; 48(6):686-93. PubMed ID: 2249379
[TBL] [Abstract][Full Text] [Related]
53. [Severe nortriptyline poisoning in poor metabolizers of the sparteine type].
Petersen P; Brøsen K
Ugeskr Laeger; 1991 Feb; 153(6):443-4. PubMed ID: 2000655
[TBL] [Abstract][Full Text] [Related]
54. Intra- and interethnic variability in reduced haloperidol to haloperidol ratios.
Lam YW; Jann MW; Chang WH; Yu HS; Lin SK; Chen H; Davis CM
J Clin Pharmacol; 1995 Feb; 35(2):128-36. PubMed ID: 7751421
[TBL] [Abstract][Full Text] [Related]
55. Variability in the elimination of mianserin in elderly patients.
Begg EJ; Sharman JR; Kidd JE; Sainsbury R; Clark DW
Br J Clin Pharmacol; 1989 Apr; 27(4):445-51. PubMed ID: 2719901
[TBL] [Abstract][Full Text] [Related]
56. [The biosynthesis of sparteine].
SCHUETTE HR; BOHLMANN F; REUSCHE W
Arch Pharm Ber Dtsch Pharm Ges; 1961 Oct; 294/66():610-5. PubMed ID: 14039067
[No Abstract] [Full Text] [Related]
57. Novel sparteine-mediated enantio-dichotomic formal synthesis of R-(-)- and S-(+)-curcuphenol.
Kimachi T; Takemoto Y
J Org Chem; 2001 Apr; 66(8):2700-4. PubMed ID: 11304190
[TBL] [Abstract][Full Text] [Related]
58. Apparent mendelian recessive inheritance of sparteine metabolism in an extended Japanese family.
Chiba K; Kato J; Hashimoto K; Ishizaki T
Eur J Clin Pharmacol; 1988; 34(6):661-2. PubMed ID: 3169120
[No Abstract] [Full Text] [Related]
59. [Around the mechanism of the synergistic action carried out by the sparteine against adrenaline].
BORIANI A
Arch Sci Biol (Bologna); 1948; 32(4):260-8. PubMed ID: 18887838
[No Abstract] [Full Text] [Related]
60. [On the therapeutic action of sparteine jodomethylate].
ROCCHINI G
Minerva Med; 1949 Mar; 40(14):402-4. PubMed ID: 18144794
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
